

Regimen Reference Order – GAST - regorafenib

ARIA: GAST – [regorafenib]

Planned Course: Once daily for three weeks, then 1 week off (1 cycle = 28 days) until disease progression or unacceptable toxicity

Indication for Use: Hepatocellular Cancer Metastatic

Proceed with treatment if:

- **ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$**
- **Total bilirubin less than 2 times upper limit of normal**
- **AST/ALT less than 3 times upper limit of normal**
 - ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – GAST - regorafenib

Drug	Dose	CCMB Administration Guideline
regorafenib	160 mg	Orally once daily for 3 weeks, then 1 week off (Self-administered at home)
regorafenib (Stivarga®) available dosage strength: 40 mg tablet Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

- CBC prior to each cycle
- AST, ALT, total bilirubin
 - At start of treatment, then
 - every 2 weeks during the first 2 months of treatment, then
 - each cycle as per Physician Orders
- Blood pressure with nurse assessment
 - Weekly for first 6 weeks, then
 - monthly

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- Protect regorafenib from moisture
 - Keep desiccant in the bottle
 - Keep the bottle tightly closed after first opening
- Instruct patient to swallow the tablets with water after a low fat meal
- If blood pressure is greater than 170/95 call your cancer care team
- Reinforce applicable safe handling precautions of medication, blood and body fluids for 48 hours after completion of regorafenib

ADDITIONAL INFORMATION

- regorafenib can cause hypertension and hand-foot syndrome
- regorafenib has been associated with severe toxicities